FANGZHOU JIANKE (06086) announced that the board of directors has noted that the company's shares experienced a price increase on the Stock Exchange on September 12, 2025. The board also noted the press release issued by the company regarding its 10th H2H Medical Service Ecosystem Conference held on September 10, 2025, which included several company updates, including: (i) the company launched its proprietary "Xingshi" large model as the cornerstone for its five flagship applications (AI Medication Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search), empowering advanced clinical diagnostic support and personalized chronic disease management; (ii) establishing a strategic partnership with Innovent Biologics, integrating FANGZHOU's H2H digital health ecosystem with Innovent's weight management therapy pipeline, initially leveraging the company's Xingshi large model to provide personalized digital maintenance and adherence support for Innovent's Mazdutide, enhancing patient efficacy in China's rapidly growing weight management market; and (iii) entering into strategic cooperation with Zhejiang Otsuka Pharmaceutical Co., Ltd., combining the company's AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education plans. After making reasonable inquiries about the company under relevant circumstances, the board confirms that the information contained in the press release does not constitute insider information as required under Rule 13.09(2) of the Listing Rules or the insider information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and it is also not aware of any reasons for the increase in share trading prices, or any information that should be announced to avoid a false market in the shares, or any insider information that should be disclosed.